Form 4: Replimune Officer Sells Shares Under 10b5-1 Plan

Replimune Group Inc. Chief Commercial Officer Christopher Sarchi sold 6,500 shares of common stock for approximately $8.01 per share, as part of a pre-arranged trading plan.

Summary

• Christopher Sarchi, Chief Commercial Officer of Replimune Group, Inc., sold 6,500 shares of common stock on April 2, 2026.
• The sale was executed at a weighted average price of $8.01 per share, with individual transactions ranging from $8.00 to $8.06.
• This transaction was conducted under a Rule 10b5-1 trading plan adopted on December 15, 2025.
• Following the sale, Sarchi beneficially owns 151,588 shares of common stock, including restricted stock units.
• Sarchi also holds options for 250,425 shares, with 142,555 exercisable.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-arranged 10b5-1 plan, which is a standard practice for executives.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-impactful trading.
• The reporting person retains a significant beneficial ownership of 151,588 shares.
• The reporting person also holds substantial exercisable options for an additional 142,555 shares.

Negatives

• A significant number of shares (6,500) were disposed of by a key executive.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales, especially under Rule 10b5-1 plans, are common for executives managing their personal portfolios and can be a routine part of executive compensation realization. The key is to monitor the scale of sales relative to total holdings and the existence of a pre-arranged plan.

Stakeholder Impact

• Shareholders: The sale by a key executive might be perceived negatively, but the use of a 10b5-1 plan mitigates concerns about insider trading. The continued significant ownership by the executive suggests confidence in the company's future.

Key Dates

Keywords

Replimune Group, REPL, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Christopher Sarchi, Chief Commercial Officer, Beneficial Ownership